TY - JOUR AU - Chen, J. AU - Odenike, O. AU - Rowley, J. D. PY - 2010 DA - 2010// TI - Leukaemogenesis: more than mutant genes JO - Nat Rev Cancer VL - 10 UR - https://doi.org/10.1038/nrc2765 DO - 10.1038/nrc2765 ID - Chen2010 ER - TY - JOUR AU - Döhner, H. AU - Estey, E. AU - Grimwade, D. AU - Amadori, S. AU - Appelbaum, F. R. AU - Büchner, T. PY - 2017 DA - 2017// TI - Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-08-733196 DO - 10.1182/blood-2016-08-733196 ID - Döhner2017 ER - TY - JOUR AU - Yu, J. AU - Li, Y. AU - Li, T. AU - Li, Y. AU - Xing, H. AU - Sun, H. PY - 2020 DA - 2020// TI - Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia JO - Exp Hematol Oncol VL - 6 UR - https://doi.org/10.1186/s40164-019-0158-5 DO - 10.1186/s40164-019-0158-5 ID - Yu2020 ER - TY - JOUR AU - Han, X. AU - Li, W. AU - He, N. AU - Feng, P. AU - Pang, Y. AU - Ji, C. PY - 2018 DA - 2018// TI - Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis JO - Clin Chim Acta VL - 479 UR - https://doi.org/10.1016/j.cca.2018.01.006 DO - 10.1016/j.cca.2018.01.006 ID - Han2018 ER - TY - JOUR AU - Chung, W. AU - Kelly, A. D. AU - Kropf, P. AU - Fung, H. AU - Jelinek, J. AU - Su, X. Y. PY - 2019 DA - 2019// TI - Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia JO - Clin Epigenet VL - 11 UR - https://doi.org/10.1186/s13148-019-0704-3 DO - 10.1186/s13148-019-0704-3 ID - Chung2019 ER - TY - JOUR AU - Yang, L. AU - Shen, K. AU - Zhang, M. AU - Zhang, W. AU - Cai, H. AU - Lin, L. PY - 2019 DA - 2019// TI - Clinical features and microRNA expression patterns between AML patients with DNMT3A R882 and frameshift mutations JO - Front Oncol VL - 24 UR - https://doi.org/10.3389/fonc.2019.01133 DO - 10.3389/fonc.2019.01133 ID - Yang2019 ER - TY - JOUR AU - Folta, A. AU - Culen, M. AU - Jeziskova, I. AU - Herudkova, Z. AU - Tom, N. AU - Hlubinkova, T. PY - 2019 DA - 2019// TI - Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients JO - Br J Haematol VL - 186 ID - Folta2019 ER - TY - JOUR AU - Vetro, C. AU - Haferlach, T. AU - Meggendorfer, M. AU - Stengel, A. AU - Jeromin, S. AU - Kern, W. PY - 2020 DA - 2020// TI - Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-rearranged acute myeloid leukemia JO - Cancer Genet VL - 240 UR - https://doi.org/10.1016/j.cancergen.2019.10.006 DO - 10.1016/j.cancergen.2019.10.006 ID - Vetro2020 ER - TY - JOUR AU - Antar, A. I. AU - Otrock, Z. K. AU - Jabbour, E. AU - Mohty, M. AU - Bazarbachi, A. PY - 2020 DA - 2020// TI - FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions JO - Leukemia UR - https://doi.org/10.1038/s41375-019-0694-3 DO - 10.1038/s41375-019-0694-3 ID - Antar2020 ER - TY - JOUR AU - Darracq, A. AU - Pak, H. AU - Bourgoin, V. AU - Zmiri, F. AU - Dellaire, G. AU - Affar, E. B. PY - 2019 DA - 2019// TI - NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes JO - PLoS Genet VL - 15 UR - https://doi.org/10.1371/journal.pgen.1008463 DO - 10.1371/journal.pgen.1008463 ID - Darracq2019 ER - TY - JOUR AU - Patel, S. S. AU - Kuo, F. C. AU - Gibson, C. J. AU - Steensma, D. P. AU - Soiffer, R. J. AU - Alyea, E. P. PY - 2018 DA - 2018// TI - High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2018-01-828467 DO - 10.1182/blood-2018-01-828467 ID - Patel2018 ER - TY - JOUR AU - Cucchi, D. G. J. AU - Denys, B. AU - Kaspers, G. J. L. AU - Janssen, J. J. W. M. AU - Ossenkoppele, G. J. AU - Haas, V. PY - 2018 DA - 2018// TI - RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2017-12-819508 DO - 10.1182/blood-2017-12-819508 ID - Cucchi2018 ER - TY - JOUR AU - Boileau, M. AU - Shirinian, M. AU - Gayden, T. AU - Harutyunyan, A. S. AU - Chen, C. C. L. AU - Mikael, L. G. PY - 2019 DA - 2019// TI - Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness JO - Nat Commun VL - 10 UR - https://doi.org/10.1038/s41467-019-10705-z DO - 10.1038/s41467-019-10705-z ID - Boileau2019 ER - TY - JOUR AU - Tallman, M. PY - 2018 DA - 2018// TI - Prognostic significance of molecular markers and targeted regimens in the management of acute myeloid leukemia JO - J Natl Compr Canc Netw VL - 16 UR - https://doi.org/10.6004/jnccn.2018.0050 DO - 10.6004/jnccn.2018.0050 ID - Tallman2018 ER - TY - JOUR AU - Tallman, M. S. AU - Wang, E. S. AU - Altman, J. K. AU - Appelbaum, F. R. AU - Bhatt, V. R. AU - Bixby, D. PY - 2019 DA - 2019// TI - Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology JO - J Natl Compr Canc Netw VL - 17 UR - https://doi.org/10.6004/jnccn.2019.0028 DO - 10.6004/jnccn.2019.0028 ID - Tallman2019 ER - TY - JOUR AU - Corces-Zimmerman, M. R. AU - Hong, W. J. AU - Weissman, I. L. AU - Medeiros, B. C. AU - Majeti, R. PY - 2014 DA - 2014// TI - Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission JO - Proc Natl Acad Sci USA VL - 111 UR - https://doi.org/10.1073/pnas.1324297111 DO - 10.1073/pnas.1324297111 ID - Corces-Zimmerman2014 ER - TY - JOUR AU - Shlush, L. I. AU - Zandi, S. AU - Mitchell, A. AU - Chen, W. C. AU - Brandwein, J. M. AU - Gupta, V. PY - 2014 DA - 2014// TI - Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia JO - Nature VL - 506 UR - https://doi.org/10.1038/nature13038 DO - 10.1038/nature13038 ID - Shlush2014 ER - TY - JOUR AU - Genovese, G. AU - Kähler, A. K. AU - Handsaker, R. E. AU - Lindberg, J. AU - Rose, S. A. AU - Bakhoum, S. F. PY - 2014 DA - 2014// TI - Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1409405 DO - 10.1056/NEJMoa1409405 ID - Genovese2014 ER - TY - JOUR AU - Jaiswal, S. AU - Fontanillas, P. AU - Flannick, J. AU - Manning, A. AU - Grauman, P. V. AU - Mar, B. G. PY - 2014 DA - 2014// TI - Age-related clonal hematopoiesis associated with adverse outcomes JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1408617 DO - 10.1056/NEJMoa1408617 ID - Jaiswal2014 ER - TY - JOUR AU - Xie, M. AU - Lu, C. AU - Wang, J. AU - McLellan, M. D. AU - Johnson, K. J. AU - Wendl, M. C. PY - 2014 DA - 2014// TI - Age-related mutations associated with clonal hematopoietic expansion and malignancies JO - Nat Med VL - 20 UR - https://doi.org/10.1038/nm.3733 DO - 10.1038/nm.3733 ID - Xie2014 ER - TY - JOUR AU - Buscarlet, M. AU - Provost, S. AU - Zada, Y. F. AU - Bourgoin, V. AU - Mollica, L. AU - Dubé, M. P. PY - 2018 DA - 2018// TI - Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-01-829937 DO - 10.1182/blood-2018-01-829937 ID - Buscarlet2018 ER - TY - JOUR AU - Ponziani, V. AU - Gianfaldoni, G. AU - Mannelli, F. AU - Leoni, F. AU - Ciolli, S. AU - Guglielmelli, P. PY - 2006 DA - 2006// TI - The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients JO - Leukemia VL - 20 UR - https://doi.org/10.1038/sj.leu.2404368 DO - 10.1038/sj.leu.2404368 ID - Ponziani2006 ER - TY - JOUR AU - Schlenk, R. F. AU - Kayser, S. AU - Bullinger, L. AU - Kobbe, G. AU - Casper, J. AU - Ringhoffer, M. PY - 2014 DA - 2014// TI - Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-05-578070 DO - 10.1182/blood-2014-05-578070 ID - Schlenk2014 ER - TY - JOUR AU - Fischer, T. AU - Stone, R. M. AU - Deangelo, D. J. AU - Galinsky, I. AU - Estey, E. AU - Lanza, C. PY - 2010 DA - 2010// TI - Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3 JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.9678 DO - 10.1200/JCO.2010.28.9678 ID - Fischer2010 ER - TY - JOUR AU - Boddu, P. C. AU - Kadia, T. M. AU - Garcia-Manero, G. AU - Cortes, J. AU - Alfayez, M. AU - Borthakur, G. PY - 2019 DA - 2019// TI - Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes JO - Cancer VL - 125 UR - https://doi.org/10.1002/cncr.31885 DO - 10.1002/cncr.31885 ID - Boddu2019 ER - TY - JOUR AU - Niparuck, P. AU - Limsuwanachot, N. AU - Pukiat, S. AU - Chantrathammachart, P. AU - Rerkamnuaychoke, B. AU - Magmuang, S. PY - 2019 DA - 2019// TI - Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia JO - Exp Hematol Oncol VL - 30 UR - https://doi.org/10.1186/s40164-019-0127-z DO - 10.1186/s40164-019-0127-z ID - Niparuck2019 ER - TY - JOUR AU - Pratcorona, M. AU - Brunet, S. AU - Nomdedéu, J. AU - Ribera, J. M. AU - Tormo, M. AU - Duarte, R. PY - 2013 DA - 2013// TI - Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-06-431122 DO - 10.1182/blood-2012-06-431122 ID - Pratcorona2013 ER - TY - JOUR AU - Boddu, P. AU - Kantarjian, H. AU - Borthakur, G. AU - Kadia, T. AU - Daver, N. AU - Pierce, S. PY - 2017 DA - 2017// TI - Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group JO - Blood Adv VL - 1 UR - https://doi.org/10.1182/bloodadvances.2017009019 DO - 10.1182/bloodadvances.2017009019 ID - Boddu2017 ER - TY - JOUR AU - Blau, O. AU - Berenstein, R. AU - Sindram, A. AU - Blau, I. W. PY - 2013 DA - 2013// TI - Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia JO - Leuk Lymphoma VL - 54 UR - https://doi.org/10.3109/10428194.2012.704999 DO - 10.3109/10428194.2012.704999 ID - Blau2013 ER - TY - JOUR AU - Schranz, K. AU - Hubmann, M. AU - Harin, E. AU - Vosberg, S. AU - Herold, T. AU - Metzeler, K. H. PY - 2018 DA - 2018// TI - Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia JO - Oncotarget VL - 9 UR - https://doi.org/10.18632/oncotarget.25729 DO - 10.18632/oncotarget.25729 ID - Schranz2018 ER - TY - JOUR AU - Lucena-Araujo, A. R. AU - Coelho-Silva, J. L. AU - Pereira-Martins, D. A. AU - Silveira, D. R. AU - Koury, L. C. AU - Melo, R. A. M. PY - 2019 DA - 2019// TI - Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia JO - Blood VL - 134 UR - https://doi.org/10.1182/blood.2019000239 DO - 10.1182/blood.2019000239 ID - Lucena-Araujo2019 ER - TY - JOUR AU - He, X. AU - Zhu, Y. AU - Lin, Y. C. AU - Li, M. AU - Du, J. AU - Dong, H. PY - 2019 DA - 2019// TI - PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia JO - Blood VL - 134 UR - https://doi.org/10.1182/blood.2019001282 DO - 10.1182/blood.2019001282 ID - He2019 ER - TY - JOUR AU - Rudorf, A. AU - Müller, T. A. AU - Klingeberg, C. AU - Kreutmair, S. AU - Poggio, T. AU - Gorantla, S. P. PY - 2019 DA - 2019// TI - NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia JO - Blood VL - 134 UR - https://doi.org/10.1182/blood.2018883140 DO - 10.1182/blood.2018883140 ID - Rudorf2019 ER - TY - JOUR AU - Wang, H. AU - Chu, T. T. AU - Han, S. Y. AU - Qi, J. Q. AU - Tang, Y. Q. AU - Qiu, H. Y. PY - 2019 DA - 2019// TI - FLT3-ITD and CEBPA mutations predict prognosis in acute myelogenous leukemia irrespective of hematopoietic stem cell transplantation JO - Biol Blood Marrow Transplant VL - 25 UR - https://doi.org/10.1016/j.bbmt.2018.11.031 DO - 10.1016/j.bbmt.2018.11.031 ID - Wang2019 ER - TY - JOUR AU - Christen, F. AU - Hoyer, K. AU - Yoshida, K. AU - Hou, H. A. AU - Waldhueter, N. AU - Heuser, M. PY - 2019 DA - 2019// TI - Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients JO - Blood VL - 133 UR - https://doi.org/10.1182/blood-2018-05-852822 DO - 10.1182/blood-2018-05-852822 ID - Christen2019 ER - TY - JOUR AU - Lyu, M. AU - Liao, H. AU - Shuai, X. AU - Jin, Y. AU - Su, J. AU - Zheng, Q. PY - 2020 DA - 2020// TI - The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan JO - Gene VL - 5 UR - https://doi.org/10.1016/j.gene.2019.144195 DO - 10.1016/j.gene.2019.144195 ID - Lyu2020 ER - TY - JOUR AU - Stone, R. M. AU - Mandrekar, S. J. AU - Sanford, B. L. AU - Laumann, K. AU - Geyer, S. AU - Bloomfield, C. D. PY - 2017 DA - 2017// TI - Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1614359 DO - 10.1056/NEJMoa1614359 ID - Stone2017 ER - TY - JOUR AU - Schlenk, R. F. AU - Weber, D. AU - Fiedler, W. AU - Salih, H. R. AU - Wulf, G. AU - Salwender, H. PY - 2019 DA - 2019// TI - Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD JO - Blood VL - 133 UR - https://doi.org/10.1182/blood-2018-08-869453 DO - 10.1182/blood-2018-08-869453 ID - Schlenk2019 ER - TY - JOUR AU - Shimada, A. PY - 2019 DA - 2019// TI - Hematological malignancies and molecular targeting therapy JO - Eur J Pharmacol VL - 862 UR - https://doi.org/10.1016/j.ejphar.2019.172641 DO - 10.1016/j.ejphar.2019.172641 ID - Shimada2019 ER - TY - JOUR AU - Fiedler, W. AU - Kayser, S. AU - Kebenko, M. AU - Janning, M. AU - Krauter, J. AU - Schittenhelm, M. PY - 2015 DA - 2015// TI - A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations JO - Br J Haematol VL - 169 UR - https://doi.org/10.1111/bjh.13353 DO - 10.1111/bjh.13353 ID - Fiedler2015 ER - TY - JOUR AU - Fiedler, W. AU - Serve, H. AU - Döhner, H. AU - Schwittay, M. AU - Ottmann, O. G. AU - O’Farrell, A. M. PY - 2005 DA - 2005// TI - A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease JO - Blood VL - 105 UR - https://doi.org/10.1182/blood-2004-05-1846 DO - 10.1182/blood-2004-05-1846 ID - Fiedler2005 ER - TY - JOUR AU - Perl, A. E. AU - Martinelli, G. AU - Cortes, J. E. AU - Neubauer, A. AU - Berman, E. AU - Paolini, S. PY - 2019 DA - 2019// TI - Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1902688 DO - 10.1056/NEJMoa1902688 ID - Perl2019 ER - TY - JOUR AU - Sidaway, P. PY - 2020 DA - 2020// TI - Gilteritinib improves outcomes in AML JO - Nat Rev Clin Oncol VL - 17 ID - Sidaway2020 ER - TY - JOUR AU - Knapper, S. AU - Russell, N. AU - Gilkes, A. AU - Hills, R. K. AU - Gale, R. E. AU - Cavenagh, J. D. PY - 2017 DA - 2017// TI - A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-07-730648 DO - 10.1182/blood-2016-07-730648 ID - Knapper2017 ER - TY - JOUR AU - Levis, M. AU - Ravandi, F. AU - Wang, E. S. AU - Baer, M. R. AU - Perl, A. AU - Coutre, S. PY - 2011 DA - 2011// TI - Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-08-301796 DO - 10.1182/blood-2010-08-301796 ID - Levis2011 ER - TY - JOUR AU - Nakao, M. AU - Yokota, S. AU - Iwai, T. AU - Kaneko, H. AU - Horiike, S. AU - Kashima, K. PY - 1996 DA - 1996// TI - Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia JO - Leukemia VL - 10 ID - Nakao1996 ER - TY - JOUR AU - Wang, E. S. PY - 2019 DA - 2019// TI - Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia JO - Best Pract Res Clin Haematol VL - 32 UR - https://doi.org/10.1016/j.beha.2019.05.006 DO - 10.1016/j.beha.2019.05.006 ID - Wang2019 ER - TY - JOUR AU - Cortes, J. E. AU - Tallman, M. S. AU - Schiller, G. J. AU - Trone, D. AU - Gammon, G. AU - Goldberg, S. L. PY - 2018 DA - 2018// TI - Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-01-821629 DO - 10.1182/blood-2018-01-821629 ID - Cortes2018 ER - TY - JOUR AU - Cortes, J. AU - Perl, A. E. AU - Döhner, H. AU - Kantarjian, H. AU - Martinelli, G. AU - Kovacsovics, T. PY - 2018 DA - 2018// TI - Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30240-7 DO - 10.1016/S1470-2045(18)30240-7 ID - Cortes2018 ER - TY - JOUR AU - Zhou, F. AU - Ge, Z. AU - Chen, B. PY - 2019 DA - 2019// TI - Quizartinib (AC220): a promising option for acute myeloid leukemia JO - Drug Des Dev Ther VL - 13 UR - https://doi.org/10.2147/DDDT.S198950 DO - 10.2147/DDDT.S198950 ID - Zhou2019 ER - TY - JOUR AU - Cortes, J. E. AU - Khaled, S. AU - Martinelli, G. AU - Perl, A. E. AU - Ganguly, S. AU - Russell, N. PY - 2019 DA - 2019// TI - Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial JO - Lancet Oncol VL - 20 UR - https://doi.org/10.1016/S1470-2045(19)30150-0 DO - 10.1016/S1470-2045(19)30150-0 ID - Cortes2019 ER - TY - JOUR AU - Sasaki, K. AU - Kantarjian, H. M. AU - Kadia, T. AU - Patel, K. AU - Loghavi, S. AU - Garcia-Manero, G. PY - 2019 DA - 2019// TI - Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia JO - Cancer VL - 125 UR - https://doi.org/10.1002/cncr.32387 DO - 10.1002/cncr.32387 ID - Sasaki2019 ER - TY - JOUR AU - Xuan, L. AU - Wang, Y. AU - Chen, J. AU - Jiang, E. AU - Gao, L. AU - Wu, B. PY - 2019 DA - 2019// TI - Sorafenib therapy is associated with improved outcomes for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation JO - Biol Blood Marrow Transplant VL - 25 UR - https://doi.org/10.1016/j.bbmt.2019.04.018 DO - 10.1016/j.bbmt.2019.04.018 ID - Xuan2019 ER - TY - JOUR AU - Ok, C. Y. AU - Patel, K. P. AU - Garcia-Manero, G. AU - Routbort, M. J. AU - Peng, J. AU - Tang, G. PY - 2015 DA - 2015// TI - TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0139-z DO - 10.1186/s13045-015-0139-z ID - Ok2015 ER - TY - JOUR AU - Zhang, L. AU - McGraw, K. L. AU - Sallman, D. A. AU - List, A. F. PY - 2017 DA - 2017// TI - The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications JO - Leuk Lymphoma VL - 58 UR - https://doi.org/10.1080/10428194.2016.1266625 DO - 10.1080/10428194.2016.1266625 ID - Zhang2017 ER - TY - JOUR AU - Kadia, T. M. AU - Jain, P. AU - Ravandi, F. AU - Garcia-Manero, G. AU - Andreef, M. AU - Takahashi, K. PY - 2016 DA - 2016// TI - TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes JO - Cancer VL - 122 UR - https://doi.org/10.1002/cncr.30203 DO - 10.1002/cncr.30203 ID - Kadia2016 ER - TY - JOUR AU - Chan, O. AU - Hunter, A. AU - Talati, C. AU - Sallman, D. A. AU - Asghari, H. AU - Song, J. PY - 2019 DA - 2019// TI - Impact of TP53 gene mutation clearance and conditioning intensity on outcome in MDS or AML patients prior to allogeneic stem cell transplantation JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-131530 DO - 10.1182/blood-2019-131530 ID - Chan2019 ER - TY - JOUR AU - Yan, B. AU - Chen, Q. AU - Xu, J. AU - Li, W. AU - Xu, B. AU - Huang, S. PY - 2019 DA - 2019// TI - Residual TP53 mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-127511 DO - 10.1182/blood-2019-127511 ID - Yan2019 ER - TY - JOUR AU - Asghari, H. AU - Talati, C. PY - 2020 DA - 2020// TI - Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics JO - Curr Opin Hematol VL - 27 UR - https://doi.org/10.1097/MOH.0000000000000568 DO - 10.1097/MOH.0000000000000568 ID - Asghari2020 ER - TY - JOUR AU - Konstandin, N. P. AU - Pastore, F. AU - Herold, T. AU - Dufour, A. AU - Rothenberg-Thurley, M. AU - Hinrichsen, T. PY - 2018 DA - 2018// TI - Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA JO - Blood Adv VL - 2 UR - https://doi.org/10.1182/bloodadvances.2018016840 DO - 10.1182/bloodadvances.2018016840 ID - Konstandin2018 ER - TY - JOUR AU - Li, H. Y. AU - Deng, D. H. AU - Huang, Y. AU - Ye, F. H. AU - Huang, L. L. AU - Xiao, Q. PY - 2015 DA - 2015// TI - Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis JO - Eur J Haematol VL - 94 UR - https://doi.org/10.1111/ejh.12450 DO - 10.1111/ejh.12450 ID - Li2015 ER - TY - JOUR AU - Dufour, A. AU - Schneider, F. AU - Metzeler, K. H. AU - Hoster, E. AU - Schneider, S. AU - Zellmeier, E. AU - Benthaus, T. AU - Sauerland, M. C. PY - 2010 DA - 2010// TI - Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2008.21.6010 DO - 10.1200/JCO.2008.21.6010 ID - Dufour2010 ER - TY - JOUR AU - Greif, P. A. AU - Dufour, A. AU - Konstandin, N. P. AU - Ksienzyk, B. AU - Zellmeier, E. AU - Tizazu, B. PY - 2012 DA - 2012// TI - GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-01-403220 DO - 10.1182/blood-2012-01-403220 ID - Greif2012 ER - TY - JOUR AU - Mannelli, F. AU - Ponziani, V. AU - Bencini, S. AU - Bonetti, M. I. AU - Benelli, M. AU - Cutini, I. PY - 2017 DA - 2017// TI - CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features JO - Haematologica VL - 102 UR - https://doi.org/10.3324/haematol.2016.151910 DO - 10.3324/haematol.2016.151910 ID - Mannelli2017 ER - TY - JOUR AU - Tarlock, K. AU - Alonzo, T. A. AU - Wang, Y. C. AU - Gerbing, R. B. AU - Ries, R. E. AU - Hylkema, T. A. PY - 2019 DA - 2019// TI - Somatic Bzip mutations of CEBPA are associated with favorable outcome regardless of presence as single vs double mutation JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-126273 DO - 10.1182/blood-2019-126273 ID - Tarlock2019 ER - TY - JOUR AU - Green, C. L. AU - Koo, K. K. AU - Hills, R. K. AU - Burnett, A. K. AU - Linch, D. C. AU - Gale, R. E. PY - 2010 DA - 2010// TI - Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.2501 DO - 10.1200/JCO.2009.26.2501 ID - Green2010 ER - TY - JOUR AU - Hollink, I. H. AU - Heuvel-Eibrink, M. M. AU - Arentsen-Peters, S. T. AU - Zimmermann, M. AU - Peeters, J. K. AU - Valk, P. J. PY - 2011 DA - 2011// TI - Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia JO - Haematologica VL - 96 UR - https://doi.org/10.3324/haematol.2010.031336 DO - 10.3324/haematol.2010.031336 ID - Hollink2011 ER - TY - JOUR AU - Arber, D. A. PY - 2019 DA - 2019// TI - The 2016 WHO classification of acute myeloid leukemia: what the practicing clinician needs to know JO - Semin Hematol VL - 56 UR - https://doi.org/10.1053/j.seminhematol.2018.08.002 DO - 10.1053/j.seminhematol.2018.08.002 ID - Arber2019 ER - TY - JOUR AU - Chan, S. M. AU - Majeti, R. PY - 2013 DA - 2013// TI - Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia JO - Int J Hematol VL - 98 UR - https://doi.org/10.1007/s12185-013-1407-8 DO - 10.1007/s12185-013-1407-8 ID - Chan2013 ER - TY - JOUR AU - Metzeler, K. H. AU - Herold, T. AU - Rothenberg-Thurley, M. AU - Amler, S. AU - Sauerland, M. C. AU - Görlich, D. PY - 2016 DA - 2016// TI - Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia JO - Blood VL - 128 UR - https://doi.org/10.1182/blood-2016-01-693879 DO - 10.1182/blood-2016-01-693879 ID - Metzeler2016 ER - TY - JOUR AU - Heath, E. M. AU - Chan, S. M. AU - Minden, M. D. AU - Murphy, T. AU - Shlush, L. I. AU - Schimmer, A. D. PY - 2017 DA - 2017// TI - Biological and clinical consequences of NPM1 mutations in AML JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2017.30 DO - 10.1038/leu.2017.30 ID - Heath2017 ER - TY - JOUR AU - Ivey, A. AU - Hills, R. K. AU - Simpson, M. A. AU - Jovanovic, J. V. AU - Gilkes, A. AU - Grech, A. PY - 2016 DA - 2016// TI - Assessment of minimal residual disease in standard-risk AML JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1507471 DO - 10.1056/NEJMoa1507471 ID - Ivey2016 ER - TY - JOUR AU - Abdelhakim, H. AU - Elkhanany, A. AU - Telfah, M. AU - Lin, T. L. AU - Godwin, A. K. PY - 2019 DA - 2019// TI - Older patients with NPM1 mutated AML have distinctive genomic mutation landscape associated with enrichment in immunosuppressive gene signature JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-131296 DO - 10.1182/blood-2019-131296 ID - Abdelhakim2019 ER - TY - JOUR AU - Eisfeld, A. K. AU - Kohlschmidt, J. AU - Mrózek, K. AU - Nicolet, D. AU - Mims, A. S. AU - Papaioannou, D. PY - 2019 DA - 2019// TI - The 2017 European leukemianet genetic risk classification performs poorly in older patients with acute myeloid leukemia (AML) and should be refined to identify patients requiring additional or alternative treatment JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-130076 DO - 10.1182/blood-2019-130076 ID - Eisfeld2019 ER - TY - JOUR AU - Lam, K. AU - Zhang, D. E. PY - 2012 DA - 2012// TI - RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis JO - Front Biosci VL - 17 UR - https://doi.org/10.2741/3977 DO - 10.2741/3977 ID - Lam2012 ER - TY - JOUR AU - Martinez-Soria, N. AU - McKenzie, L. AU - Draper, J. AU - Ptasinska, A. AU - Issa, H. AU - Potluri, S. PY - 2018 DA - 2018// TI - The oncogenic transcription factor RUNX1/ETO corrupts cell cycle regulation to drive leukemic transformation JO - Cancer Cell VL - 34 UR - https://doi.org/10.1016/j.ccell.2018.08.015 DO - 10.1016/j.ccell.2018.08.015 ID - Martinez-Soria2018 ER - TY - JOUR AU - Schnittger, S. AU - Dicker, F. AU - Kern, W. AU - Wendland, N. AU - Sundermann, J. AU - Alpermann, T. PY - 2011 DA - 2011// TI - RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2009-11-255976 DO - 10.1182/blood-2009-11-255976 ID - Schnittger2011 ER - TY - JOUR AU - Jalili, M. AU - Yaghmaie, M. AU - Ahmadvand, M. AU - Alimoghaddam, K. AU - Mousavi, S. A. AU - Vaezi, M. PY - 2018 DA - 2018// TI - Prognostic value of RUNX1 mutations in AML: a meta-analysis JO - Asian Pac J Cancer Prev VL - 19 ID - Jalili2018 ER - TY - JOUR AU - Simon, L. AU - Lavallée, V. P. AU - Bordeleau, M. E. AU - Krosl, J. AU - Baccelli, I. AU - Boucher, G. PY - 2017 DA - 2017// TI - Chemogenomic landscape of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-1259 DO - 10.1158/1078-0432.CCR-17-1259 ID - Simon2017 ER - TY - JOUR AU - Montalban-Bravo, G. AU - DiNardo, C. D. PY - 2018 DA - 2018// TI - The role of IDH mutations in acute myeloid leukemia JO - Future Oncol VL - 14 UR - https://doi.org/10.2217/fon-2017-0523 DO - 10.2217/fon-2017-0523 ID - Montalban-Bravo2018 ER - TY - JOUR AU - Mason, E. F. AU - Kuo, F. C. AU - Hasserjian, R. P. AU - Seegmiller, A. C. AU - Pozdnyakova, O. PY - 2018 DA - 2018// TI - A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome JO - Am J Hematol VL - 93 UR - https://doi.org/10.1002/ajh.25018 DO - 10.1002/ajh.25018 ID - Mason2018 ER - TY - JOUR AU - Sharma, H. PY - 2018 DA - 2018// TI - Development of novel therapeutics targeting isocitrate dehydrogenase mutations in cancer JO - Curr Top Med Chem VL - 18 UR - https://doi.org/10.2174/1568026618666180518091144 DO - 10.2174/1568026618666180518091144 ID - Sharma2018 ER - TY - JOUR AU - Medeiros, B. C. AU - Fathi, A. T. AU - DiNardo, C. D. AU - Pollyea, D. A. AU - Chan, S. M. AU - Swords, R. PY - 2017 DA - 2017// TI - Isocitrate dehydrogenase mutations in myeloid malignancies JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2016.275 DO - 10.1038/leu.2016.275 ID - Medeiros2017 ER - TY - JOUR AU - Roboz, G. J. AU - DiNardo, C. D. AU - Stein, E. M. AU - Botton, S. AU - Mims, A. S. AU - Prince, G. T. PY - 2019 DA - 2019// TI - Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia JO - Blood UR - https://doi.org/10.1182/blood.2019002140 DO - 10.1182/blood.2019002140 ID - Roboz2019 ER - TY - JOUR AU - DiNardo, C. D. AU - Stein, E. M. AU - Botton, S. AU - Roboz, G. J. AU - Altman, J. K. AU - Mims, A. S. PY - 2018 DA - 2018// TI - Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1716984 DO - 10.1056/NEJMoa1716984 ID - DiNardo2018 ER - TY - JOUR AU - Stein, E. M. AU - DiNardo, C. D. AU - Fathi, A. T. AU - Pollyea, D. A. AU - Stone, R. M. AU - Altman, J. K. AU - Roboz, G. J. AU - Patel, M. R. AU - Collins, R. AU - Flinn, I. W. AU - Sekeres, M. A. AU - Stein, A. S. AU - Kantarjian, H. M. AU - Levine, R. L. AU - Vyas, P. AU - MacBeth, K. J. AU - Tosolini, A. AU - Oostendorp, J. AU - Xu, Q. AU - Gupta, I. AU - Lila, T. AU - Risueno, A. AU - Yen, K. E. AU - Wu, B. AU - Attar, E. C. AU - Tallman, M. S. AU - Botton, S. PY - 2019 DA - 2019// TI - Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib JO - Blood VL - 133 UR - https://doi.org/10.1182/blood-2018-08-869008 DO - 10.1182/blood-2018-08-869008 ID - Stein2019 ER - TY - JOUR AU - Pollyea, D. A. AU - Tallman, M. S. AU - Botton, S. AU - Kantarjian, H. M. AU - Collins, R. AU - Stein, A. S. PY - 2019 DA - 2019// TI - Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia JO - Leukemia VL - 33 UR - https://doi.org/10.1038/s41375-019-0472-2 DO - 10.1038/s41375-019-0472-2 ID - Pollyea2019 ER - TY - JOUR AU - Abou Dalle, I. AU - DiNardo, C. D. PY - 2018 DA - 2018// TI - The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia JO - Ther Adv Hematol VL - 9 UR - https://doi.org/10.1177/2040620718777467 DO - 10.1177/2040620718777467 ID - Abou Dalle2018 ER - TY - JOUR AU - Reed, D. R. AU - Elsarrag, R. Z. AU - Morris, A. L. AU - Keng, M. K. PY - 2019 DA - 2019// TI - Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment JO - Cancer Manag Res VL - 11 UR - https://doi.org/10.2147/CMAR.S162784 DO - 10.2147/CMAR.S162784 ID - Reed2019 ER - TY - STD TI - Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. Olutasidenib (FT-2102), an IDH1m inhibitor as a single agent or in combination with azacitidine, induces deep clinical researches with mutation clearance in patients with acute myeloid leukemia treated in a phase 1 dose escalation and expansion study. In: Presented at the 61st annual meeting of the American Society of Hematology, December 7–10, 2019, Orlando, FL (abstract 616). ID - ref90 ER - TY - JOUR AU - Holz-Schietinger, C. AU - Matje, D. M. AU - Reich, N. O. PY - 2012 DA - 2012// TI - Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation JO - J Biol Chem VL - 287 UR - https://doi.org/10.1074/jbc.M112.366625 DO - 10.1074/jbc.M112.366625 ID - Holz-Schietinger2012 ER - TY - JOUR AU - Kim, S. J. AU - Zhao, H. AU - Hardikar, S. AU - Singh, A. K. AU - Goodell, M. A. AU - Chen, T. PY - 2013 DA - 2013// TI - A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-02-483487 DO - 10.1182/blood-2013-02-483487 ID - Kim2013 ER - TY - JOUR AU - Ley, T. J. AU - Ding, L. AU - Walter, M. J. AU - McLellan, M. D. AU - Lamprecht, T. AU - Larson, D. E. PY - 2010 DA - 2010// TI - DNMT3A mutations in acute myeloid leukemia JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1005143 DO - 10.1056/NEJMoa1005143 ID - Ley2010 ER - TY - JOUR AU - Patel, J. P. AU - Gonen, M. AU - Figueroa, M. E. AU - Fernandez, H. AU - Sun, Z. AU - Racevskis, J. PY - 2012 DA - 2012// TI - Prognostic relevance of integrated genetic profiling in acute myeloid leukemia JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1112304 DO - 10.1056/NEJMoa1112304 ID - Patel2012 ER - TY - JOUR AU - Gaidzik, V. I. AU - Schlenk, R. F. AU - Paschka, P. AU - Stölzle, A. AU - Späth, D. AU - Lilienfeld-Toal, M. PY - 2013 DA - 2013// TI - Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML study group (AMLSG) JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-10-461624 DO - 10.1182/blood-2012-10-461624 ID - Gaidzik2013 ER - TY - JOUR AU - Gale, R. E. AU - Lamb, K. AU - Allen, C. AU - El-Sharkawi, D. AU - Stowe, C. AU - Jenkinson, S. PY - 2015 DA - 2015// TI - Simpson’s paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.2022 DO - 10.1200/JCO.2014.59.2022 ID - Gale2015 ER - TY - JOUR AU - Zhang, X. AU - Wang, X. AU - Wang, X. Q. D. AU - Su, J. AU - Putluri, N. AU - Zhou, T. PY - 2020 DA - 2020// TI - Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis JO - Blood UR - https://doi.org/10.1182/blood.2019003330 DO - 10.1182/blood.2019003330 ID - Zhang2020 ER - TY - JOUR AU - Bolouri, H. AU - Farrar, J. E. AU - Triche, T. AU - Ries, R. E. AU - Lim, E. L. AU - Alonzo, T. A. PY - 2018 DA - 2018// TI - The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions JO - Nat Med VL - 24 UR - https://doi.org/10.1038/nm.4439 DO - 10.1038/nm.4439 ID - Bolouri2018 ER - TY - JOUR AU - Basecke, J. AU - Whelan, J. T. AU - Griesinger, F. AU - Bertrand, F. E. PY - 2006 DA - 2006// TI - The MLL partial tandem duplication in acute myeloid leukaemia JO - Br J Haematol VL - 135 UR - https://doi.org/10.1111/j.1365-2141.2006.06301.x DO - 10.1111/j.1365-2141.2006.06301.x ID - Basecke2006 ER - TY - JOUR AU - Hinai, A. S. A. A. AU - Pratcorona, M. AU - Grob, T. AU - Kavelaars, F. G. AU - Bussaglia, E. AU - Sanders, M. A. PY - 2019 DA - 2019// TI - The landscape of KMT2A-PTD AML: concurrent mutations, gene expression signatures, and clinical outcome JO - Hemasphere VL - 3 UR - https://doi.org/10.1097/HS9.0000000000000181 DO - 10.1097/HS9.0000000000000181 ID - Hinai2019 ER - TY - JOUR AU - Zhang, Y. AU - Yan, X. AU - Sashida, G. AU - Zhao, X. AU - Rao, Y. AU - Goyama, S. PY - 2012 DA - 2012// TI - Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-02-412379 DO - 10.1182/blood-2012-02-412379 ID - Zhang2012 ER - TY - JOUR AU - Gilliland, D. G. PY - 2001 DA - 2001// TI - Hematologic malignancies JO - Curr Opin Hematol VL - 8 UR - https://doi.org/10.1097/00062752-200107000-00001 DO - 10.1097/00062752-200107000-00001 ID - Gilliland2001 ER - TY - JOUR AU - Sakhdari, A. AU - Tang, Z. AU - Ok, C. Y. AU - Bueso-Ramos, C. E. AU - Medeiros, L. J. AU - Huh, Y. O. PY - 2019 DA - 2019// TI - Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) JO - Cancer Genet VL - 238 UR - https://doi.org/10.1016/j.cancergen.2019.07.001 DO - 10.1016/j.cancergen.2019.07.001 ID - Sakhdari2019 ER - TY - JOUR AU - Schnittger, S. AU - Eder, C. AU - Jeromin, S. AU - Alpermann, T. AU - Fasan, A. AU - Grossmann, V. PY - 2013 DA - 2013// TI - ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2012.262 DO - 10.1038/leu.2012.262 ID - Schnittger2013 ER - TY - JOUR AU - Metzeler, K. H. AU - Becker, H. AU - Maharry, K. AU - Radmacher, M. D. AU - Kohlschmidt, J. AU - Mrózek, K. PY - 2011 DA - 2011// TI - ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-08-368225 DO - 10.1182/blood-2011-08-368225 ID - Metzeler2011 ER - TY - JOUR AU - Kakosaiou, K. AU - Panitsas, F. AU - Daraki, A. AU - Pagoni, M. AU - Apostolou, P. AU - Ioannidou, A. PY - 2018 DA - 2018// TI - ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics JO - Leuk Lymphoma VL - 59 UR - https://doi.org/10.1080/10428194.2018.1433298 DO - 10.1080/10428194.2018.1433298 ID - Kakosaiou2018 ER - TY - JOUR AU - Paschka, P. AU - Schlenk, R. F. AU - Gaidzik, V. I. AU - Herzig, J. K. AU - Aulitzky, T. AU - Bullinger, L. PY - 2015 DA - 2015// TI - ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian acute myeloid leukemia study group JO - Haematologica VL - 100 UR - https://doi.org/10.3324/haematol.2014.114157 DO - 10.3324/haematol.2014.114157 ID - Paschka2015 ER - TY - JOUR AU - Chou, W. C. AU - Huang, H. H. AU - Hou, H. A. AU - Chen, C. Y. AU - Tang, J. L. AU - Yao, M. PY - 2010 DA - 2010// TI - Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2010-05-283291 DO - 10.1182/blood-2010-05-283291 ID - Chou2010 ER - TY - JOUR AU - Sasaki, K. AU - Kanagal-Shamanna, R. AU - Montalban-Bravo, G. AU - Assi, R. AU - Jabbour, E. AU - Ravandi, F. PY - 2020 DA - 2020// TI - Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia JO - Cancer VL - 126 UR - https://doi.org/10.1002/cncr.32566 DO - 10.1002/cncr.32566 ID - Sasaki2020 ER - TY - JOUR AU - Asada, S. AU - Fujino, T. AU - Goyama, S. AU - Kitamura, T. PY - 2019 DA - 2019// TI - The role of ASXL1 in hematopoiesis and myeloid malignancies JO - Cell Mol Life Sci VL - 76 UR - https://doi.org/10.1007/s00018-019-03084-7 DO - 10.1007/s00018-019-03084-7 ID - Asada2019 ER - TY - JOUR AU - Nagase, R. AU - Inoue, D. AU - Pastore, A. AU - Fujino, T. AU - Hou, H. A. AU - Yamasaki, N. PY - 2018 DA - 2018// TI - Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation JO - J Exp Med VL - 215 UR - https://doi.org/10.1084/jem.20171151 DO - 10.1084/jem.20171151 ID - Nagase2018 ER - TY - JOUR AU - Montes-Moreno, S. AU - Routbort, M. J. AU - Lohman, E. J. AU - Barkoh, B. A. AU - Kanagal-Shamanna, R. AU - Bueso-Ramos, C. E. PY - 2018 DA - 2018// TI - Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era JO - PLoS ONE VL - 13 UR - https://doi.org/10.1371/journal.pone.0204218 DO - 10.1371/journal.pone.0204218 ID - Montes-Moreno2018 ER - TY - JOUR AU - Bullinger, L. AU - Döhner, K. AU - Döhner, H. PY - 2017 DA - 2017// TI - Genomics of acute myeloid leukemia diagnosis and pathways JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.71.2208 DO - 10.1200/JCO.2016.71.2208 ID - Bullinger2017 ER - TY - JOUR AU - Medinger, M. AU - Passweg, J. R. PY - 2017 DA - 2017// TI - Acute myeloid leukaemia genomics JO - Br J Haematol VL - 179 UR - https://doi.org/10.1111/bjh.14823 DO - 10.1111/bjh.14823 ID - Medinger2017 ER - TY - JOUR AU - Asada, S. AU - Goyama, S. AU - Inoue, D. AU - Shikata, S. AU - Takeda, R. AU - Fukushima, T. PY - 2018 DA - 2018// TI - Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-05085-9 DO - 10.1038/s41467-018-05085-9 ID - Asada2018 ER - TY - JOUR AU - Inoue, D. AU - Fujino, T. AU - Sheridan, P. AU - Zhang, Y. Z. AU - Nagase, R. AU - Horikawa, S. PY - 2018 DA - 2018// TI - A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies JO - Leukemia VL - 32 UR - https://doi.org/10.1038/s41375-018-0083-3 DO - 10.1038/s41375-018-0083-3 ID - Inoue2018 ER - TY - JOUR AU - Saika, M. AU - Inoue, D. AU - Nagase, R. AU - Sato, N. AU - Tsuchiya, A. AU - Yabushita, T. PY - 2018 DA - 2018// TI - ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation JO - Sci Rep VL - 8 UR - https://doi.org/10.1038/s41598-018-33881-2 DO - 10.1038/s41598-018-33881-2 ID - Saika2018 ER - TY - JOUR AU - Yang, H. AU - Kurtenbach, S. AU - Guo, Y. AU - Lohse, I. AU - Durante, M. A. AU - Li, J. PY - 2018 DA - 2018// TI - Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2017-06-789669 DO - 10.1182/blood-2017-06-789669 ID - Yang2018 ER - TY - JOUR AU - Hosono, N. PY - 2019 DA - 2019// TI - Genetic abnormalities and pathophysiology of MDS JO - Int J Clin Oncol VL - 24 UR - https://doi.org/10.1007/s10147-019-01462-6 DO - 10.1007/s10147-019-01462-6 ID - Hosono2019 ER - TY - JOUR AU - Panagopoulos, I. AU - Gorunova, L. AU - Andersen, H. K. AU - Bergrem, A. AU - Dahm, A. AU - Andersen, K. PY - 2018 DA - 2018// TI - PAN3-PSMA2 fusion resulting from a novel t(7;13)(p14;q12) chromosome translocation in a myelodysplastic syndrome that evolved into acute myeloid leukemia JO - Exp Hematol Oncol VL - 20 UR - https://doi.org/10.1186/s40164-018-0099-4 DO - 10.1186/s40164-018-0099-4 ID - Panagopoulos2018 ER - TY - JOUR AU - Panagopoulos, I. AU - Brunetti, M. AU - Stoltenberg, M. AU - Strandabø, R. A. U. AU - Staurseth, J. AU - Andersen, K. PY - 2019 DA - 2019// TI - Novel GTF2I-PDGFRB and IKZF1-TYW1 fusions in pediatric leukemia with normal karyotype JO - Exp Hematol Oncol. VL - 29 UR - https://doi.org/10.1186/s40164-019-0136-y DO - 10.1186/s40164-019-0136-y ID - Panagopoulos2019 ER -